To substantiate our in vitro and in vivo human xenograft findings, we found that the combination is effective in a MYCN-amplified neuroblastoma PDX model, which demonstrated only modest single-agent MLN8237 activity, mirroring clinical activity of MLN8237 in neuroblastoma (Mosse et al., 2012). This evidence concerns the gene MYCN and neuroblastoma.